MARAVAI LIFESCIENCES HOLDINGS, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
MRVI$7.86-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(230,762) | $(259,622) | $(138,375) |
| Other comprehensive income: | |||
| Foreign currency translation adjustments | 924 | — | — |
| Total other comprehensive loss | (229,838) | (259,622) | (138,375) |
| Comprehensive loss attributable to non-controlling interests | (99,589) | (114,776) | (19,346) |
| Total comprehensive loss attributable to Maravai LifeSciences Holdings, Inc. | $(130,249) | $(144,846) | $(119,029) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.